{
    "body": "What is the indication for Mirabegron?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26908514", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24127366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24078498", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24610862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23757386", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26665779", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26422675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23063375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25521658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23089348", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23850394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23182126", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26501573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22981677", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25791612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27124860", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24602031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26663687", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26493129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20878594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22384458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24458878"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/chebi/id/CHEBI:65349", 
            "o": "mirabegron"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C2983812", 
            "o": "http://linkedlifedata.com/resource/umls/label/A19588156"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A19588156", 
            "o": "mirabegron"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C2983812", 
            "o": "http://linkedlifedata.com/resource/umls/label/A20837597"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A20837597", 
            "o": "mirabegron"
        }
    ], 
    "ideal_answer": [
        "Mirabegron, the first \u5c3e3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", 
        "mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (oab) syndrome symptoms.", 
        "Mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", 
        "Mirabegron, the first \ufffd3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", 
        "Mirabegron, the first 3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms. "
    ], 
    "exact_answer": [
        "OverActive Bladder syndrome"
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053201"
    ], 
    "type": "factoid", 
    "id": "58f4b2f070f9fc6f0f000012", 
    "snippets": [
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 149, 
            "text": "Mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26422675", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 344, 
            "offsetInEndSection": 529, 
            "text": "The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 450, 
            "offsetInEndSection": 685, 
            "text": "Mirabegron has been approved in Japan for the indication of urgency, urinary frequency and urge urinary incontinence associated with OAB, and was recently submitted for approval to U.S. and European authorities for the same indication.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1386, 
            "offsetInEndSection": 1603, 
            "text": "Mirabegron was well tolerated.The early onset of action and good overall efficacy and tolerability balance that mirabegron offers may lead to high rates of persistence with mirabegron in the long-term treatment of OAB", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458878", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 461, 
            "text": "Mirabegron, the selective \u03b23-adrenoceptor agonist, heralds the latest development for the treatment of overactive bladder (OAB).To present the evidence available on the efficacy and tolerability of mirabegron and to discuss this treatments potential in our setting.We reviewed 11 studies conducted with mirabegron in patients with OAB (2 phase II, 9 phase III), all studies were compared to placebo with 6 studies also including tolterodine as an additional arm", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23850394", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 864, 
            "offsetInEndSection": 1386, 
            "text": "More than 50% of patients had previously discontinued anticholinergics medication for OAB, thus allowing us to obtain data on the effectiveness of mirabegron in patients already treated with anticholinergics.Mirabegron is an efficacious drug which presents a statistically significant reduction in the number of incontinence episodes and in urinary frequency as of 4 weeks, with a higher percentage of dry patients and a higher percentage of patients with reduction \u226550% in the number of incontinence episodes than placebo", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23850394", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 657, 
            "text": "Mirabegron, a \u03b2(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB).To assess the efficacy and tolerability of mirabegron versus placebo.Multicenter randomised double-blind, parallel-group placebo- and tolterodine-controlled phase 3 trial conducted in 27 countries in Europe and Australia in patients \u2265 18 yr of age with symptoms of OAB for \u2265 3 mo.After a 2-wk single-blind placebo run-in period, patients were randomised to receive placebo, mirabegron 50mg, mirabegron 100mg, or tolterodine extended release 4 mg orally once daily for 12 wk.Patients completed a micturition diary and quality-of-life (QoL) assessments.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182126", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 334, 
            "text": "Mirabegron is the first \u03b23-adrenoceptor agonist that is clinically effective for overactive bladder.The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin.Female Sprague-Dawley rats were anesthetized", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981677", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1247, 
            "offsetInEndSection": 1538, 
            "text": "Mirabegron exhibits a novel mode of action in targeting the \u03b2\u2083-AR for bladder relaxation, and the studies and trials conducted to date suggest mirabegron as a promising new treatment in the management of OAB symptoms, such as increased urinary urgency and frequency, and urgency incontinence", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20878594", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 452, 
            "offsetInEndSection": 686, 
            "text": "Mirabegron has been approved in Japan for the indication of urgency, urinary frequency and urge urinary incontinence associated with OAB, and was recently submitted for approval to U.S. and European authorities for the same indication", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 347, 
            "offsetInEndSection": 532, 
            "text": "The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 237, 
            "offsetInEndSection": 371, 
            "text": "Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26501573", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 540, 
            "text": "To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel \u03b23 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB).We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, \u03b23 receptor agonist and overactive bladder.Effect of Mirabegron on \u03b23 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078498", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 52, 
            "text": "Mirabegron for the treatment of overactive bladder.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 53, 
            "text": "Mirabegron: a Beta-3 agonist for overactive bladder.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521658", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 62, 
            "text": "[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 399, 
            "offsetInEndSection": 650, 
            "text": "Phase III clinical trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100\u2009mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127366", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 144, 
            "text": "To review the place in therapy of mirabegron, a new oral \u03b23-adrenergic receptor agonist, for the treatment of overactive bladder (OAB", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757386", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 108, 
            "text": "Mirabegron (YM178) is a \u03b2(3)-adrenoceptor agonist for the treatment of overactive bladder (OAB).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23063375", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 586, 
            "offsetInEndSection": 666, 
            "text": "Two new therapies have emerged for treating overactive bladder (OAB): Mirabegron", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089348", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 8, 
            "offsetInEndSection": 134, 
            "text": " OnabotulinumtoxinA and mirabegron have recently gained marketing authorisation to treat symptoms of overactive bladder (OAB).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908514", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1, 
            "offsetInEndSection": 188, 
            "text": "irabegron (YM-178), currently in development by Astellas Pharma Inc, is an orally active \u03b2\u2083-adrenoceptor (AR) agonist for the potential symptomatic treatment of overactive bladder (OAB). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20878594", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 166, 
            "text": "To evaluate the efficacy and safety of the \u03b23 -adrenoceptor agonist, mirabegron, compared with placebo in Japanese patients with overactive bladder (OAB).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26663687", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 180, 
            "offsetInEndSection": 284, 
            "text": "Mirabegron is the first \u03b23 -adrenoceptor agonist approved for treatment of overactive bladder syndrome. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493129", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 162, 
            "text": "To examine the effects of mirabegron, a selective \u03b23 -adrenoceptor agonist that has recently been approved for the treatment of overactive bladder (OAB", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27124860", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 14, 
            "offsetInEndSection": 122, 
            "text": "mirabegron is a \u03b23-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610862", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 113, 
            "offsetInEndSection": 191, 
            "text": "mirabegron, a \u03b23-adrenoceptor agonist for the treatment of overactive bladder,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25791612", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 3, 
            "offsetInEndSection": 237, 
            "text": "critically analyse available phase II and III randomised control trials (RCTs) reporting clinical data about the efficacy and tolerability of Mirabegron (a \u03b2\u2083-adrenoceptor agonist) in the treatment of overactive bladder (OAB) syndrome", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24602031", 
            "endSection": "abstract"
        }
    ]
}